Go Pro
→ It’s not about Greenland (From Porter & Company) (Ad)tc pixel Free NXGLW Stock Alerts

NEXGEL (NXGLW) Competitors

NEXGEL logo
$0.01 0.00 (0.00%)
As of 08/21/2026 02:24 PM Eastern
Compare

NXGLW vs. LUCYW, WOK, MDLN, ALC, and WST

Should you buy NEXGEL stock or one of its competitors? NEXGEL's main competitors and comparable companies include Innovative Eyewear (LUCYW), WORK Medical Technology Group (WOK), Medline (MDLN), Alcon (ALC), and West Pharmaceutical Services (WST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does NEXGEL compare to Innovative Eyewear?

Innovative Eyewear (NASDAQ:LUCYW) and NEXGEL (NASDAQ:NXGLW) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, Innovative Eyewear's average media sentiment score of 0.88 beat NEXGEL's score of 0.00 indicating that Innovative Eyewear is being referred to more favorably in the media.

Company Overall Sentiment
Innovative Eyewear Positive
NEXGEL Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innovative Eyewear$3.41MN/AN/AN/AN/A
NEXGEL$12.07MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Innovative EyewearN/A N/A N/A
NEXGEL N/A N/A N/A

Summary

Innovative Eyewear and NEXGEL tied by winning 1 of the 2 factors compared between the two stocks.

How does NEXGEL compare to WORK Medical Technology Group?

WORK Medical Technology Group (NASDAQ:WOK) and NEXGEL (NASDAQ:NXGLW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

NEXGEL has higher revenue and earnings than WORK Medical Technology Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WORK Medical Technology Group$9.81MN/A-$1.07MN/AN/A
NEXGEL$12.07MN/AN/AN/AN/A

In the previous week, WORK Medical Technology Group had 2 more articles in the media than NEXGEL. MarketBeat recorded 2 mentions for WORK Medical Technology Group and 0 mentions for NEXGEL. WORK Medical Technology Group's average media sentiment score of 0.52 beat NEXGEL's score of 0.00 indicating that WORK Medical Technology Group is being referred to more favorably in the media.

Company Overall Sentiment
WORK Medical Technology Group Positive
NEXGEL Neutral

Company Net Margins Return on Equity Return on Assets
WORK Medical Technology GroupN/A N/A N/A
NEXGEL N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WORK Medical Technology Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

WORK Medical Technology Group beats NEXGEL on 3 of the 4 factors compared between the two stocks.

How does NEXGEL compare to Medline?

NEXGEL (NASDAQ:NXGLW) and Medline (NASDAQ:MDLN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Medline has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$12.07MN/AN/AN/AN/A
Medline$28.43B1.58$1.16B$0.7943.37

In the previous week, Medline had 16 more articles in the media than NEXGEL. MarketBeat recorded 16 mentions for Medline and 0 mentions for NEXGEL. Medline's average media sentiment score of 0.21 beat NEXGEL's score of 0.00 indicating that Medline is being referred to more favorably in the news media.

Company Overall Sentiment
NEXGEL Neutral
Medline Neutral

Medline has a consensus target price of $47.42, suggesting a potential upside of 38.42%. Given Medline's stronger consensus rating and higher possible upside, analysts clearly believe Medline is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Medline
1 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.83

Company Net Margins Return on Equity Return on Assets
NEXGELN/A N/A N/A
Medline N/A N/A N/A

Summary

Medline beats NEXGEL on 7 of the 7 factors compared between the two stocks.

How does NEXGEL compare to Alcon?

Alcon (NYSE:ALC) and NEXGEL (NASDAQ:NXGLW) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, Alcon had 1 more articles in the media than NEXGEL. MarketBeat recorded 1 mentions for Alcon and 0 mentions for NEXGEL. Alcon's average media sentiment score of 0.59 beat NEXGEL's score of 0.00 indicating that Alcon is being referred to more favorably in the media.

Company Overall Sentiment
Alcon Positive
NEXGEL Neutral

Alcon has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alcon$10.40B3.50$980M$1.3156.18
NEXGEL$12.07MN/AN/AN/AN/A

Alcon has a net margin of 5.92% compared to NEXGEL's net margin of 0.00%. Alcon's return on equity of 7.29% beat NEXGEL's return on equity.

Company Net Margins Return on Equity Return on Assets
Alcon5.92% 7.29% 5.09%
NEXGEL N/A N/A N/A

Alcon presently has a consensus price target of $84.96, indicating a potential upside of 15.46%. Given Alcon's stronger consensus rating and higher probable upside, research analysts clearly believe Alcon is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alcon
1 Sell rating(s)
6 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.63
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

53.9% of Alcon shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Alcon beats NEXGEL on 11 of the 11 factors compared between the two stocks.

How does NEXGEL compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and NEXGEL (NASDAQ:NXGLW) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, West Pharmaceutical Services had 18 more articles in the media than NEXGEL. MarketBeat recorded 18 mentions for West Pharmaceutical Services and 0 mentions for NEXGEL. West Pharmaceutical Services' average media sentiment score of 1.59 beat NEXGEL's score of 0.00 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Overall Sentiment
West Pharmaceutical Services Very Positive
NEXGEL Neutral

West Pharmaceutical Services currently has a consensus target price of $368.08, indicating a potential upside of 4.29%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, research analysts plainly believe West Pharmaceutical Services is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.87
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

West Pharmaceutical Services has a net margin of 16.98% compared to NEXGEL's net margin of 0.00%. West Pharmaceutical Services' return on equity of 20.11% beat NEXGEL's return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services16.98% 20.11% 14.83%
NEXGEL N/A N/A N/A

West Pharmaceutical Services has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B8.08$493.70M$7.8145.19
NEXGEL$12.07MN/AN/AN/AN/A

93.9% of West Pharmaceutical Services shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

West Pharmaceutical Services beats NEXGEL on 12 of the 12 factors compared between the two stocks.

Get NEXGEL News Delivered to You Automatically

Sign up to receive the latest news and ratings for NXGLW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXGLW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NXGLW vs. The Competition

Export
MetricNEXGELHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$5.88B$7.32B$12.82B
Dividend YieldN/A1.74%2.54%10.78%
P/E RatioN/A26.54272.9024.25
Price / SalesN/A70.90632.6497.63
Price / CashN/A33.7129.0336.90
Price / BookN/A6.2211.256.42
Net IncomeN/A$149.90M$3.47B$348.89M
7 Day PerformanceN/A1.16%2.33%0.57%
1 Month PerformanceN/A9.21%7.72%4.90%
1 Year PerformanceN/A8.07%25.22%17.06%

NEXGEL Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NXGLW
NEXGEL
N/A$0.01
flat		N/A-96.2%$0.00$12.07MN/A10
LUCYW
Innovative Eyewear
N/A$0.04
-3.1%		N/AN/A$0.00$2.98MN/A9
WOK
WORK Medical Technology Group
0.9458 of 5 stars		$2.01
-2.0%		N/A-100.0%$0.00$9.81MN/A226
MDLN
Medline
3.8393 of 5 stars		$35.56
+0.2%		$47.42
+33.4%		N/A$46.70B$28.43B111.0845,000
ALC
Alcon
3.2165 of 5 stars		$73.01
-0.8%		$84.63
+15.9%		-10.3%$36.09B$10.40B55.7025,942

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NXGLW) was last updated on 8/24/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Bank of America grew this stake 139%
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel